QQQ   429.65 (-0.34%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   429.65 (-0.34%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   429.65 (-0.34%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   429.65 (-0.34%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)

Mersana Therapeutics (MRSN) Stock Price, News & Analysis

$3.71
-0.05 (-1.33%)
(As of 11:15 AM ET)
Today's Range
$3.70
$3.83
50-Day Range
$3.59
$5.94
52-Week Range
$0.80
$9.62
Volume
143,514 shs
Average Volume
2.19 million shs
Market Capitalization
$450.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.29

Mersana Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
69.4% Upside
$6.29 Price Target
Short Interest
Bearish
8.35% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.69
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.60) to ($0.67) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.09 out of 5 stars

Medical Sector

141st out of 930 stocks

Pharmaceutical Preparations Industry

51st out of 428 stocks

MRSN stock logo

About Mersana Therapeutics Stock (NASDAQ:MRSN)

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

MRSN Stock Price History

MRSN Stock News Headlines

Mersana Therapeutics Inc MRSN
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
The Analyst Verdict: Mersana Therapeutics In The Eyes Of 5 Experts
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Expert Outlook: Mersana Therapeutics Through The Eyes Of 5 Analysts
Q4 2023 Mersana Therapeutics Inc Earnings Call
Here's what Wall Street expects from Mersana Therapeutics's earnings
See More Headlines
Receive MRSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mersana Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/17/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MRSN
Fax
N/A
Employees
123
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.29
High Stock Price Target
$9.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+67.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Net Income
$-171,670,000.00
Net Margins
-465.80%
Pretax Margin
-465.80%

Debt

Sales & Book Value

Annual Sales
$36.85 million
Book Value
$0.31 per share

Miscellaneous

Free Float
106,140,000
Market Cap
$456.09 million
Optionable
Optionable
Beta
1.50
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Martin H. Huber M.D. (Age 63)
    President, CEO & Director
    Comp: $44k
  • Mr. Brian C. DeSchuytner (Age 45)
    Senior VP, CFO & COO
    Comp: $626.32k
  • Dr. Timothy B. Lowinger Ph.D. (Age 60)
    Senior VP and Chief Science & Technology Officer
    Comp: $666.3k
  • Ms. Alejandra Veronica Carvajal J.D. (Age 50)
    Senior VP, Secretary & Chief Legal Officer
    Comp: $606.51k
  • Mr. Mikhail Papisov Ph.D.
    Co-Founder
  • Mr. Ashish  MandeliaMr. Ashish Mandelia (Age 49)
    VP, Controller & Chief Accounting Officer
  • Mr. Jason Fredette
    Senior Vice President of Investor Relations & Corporate Communications
  • Mr. Chuck Miller
    Senior Vice President of Regulatory Affairs
  • Mr. Marc Damelin
    Exe. Director and Head of Biology, Oncology, Antibody-Drug Conjugate ADC Discovery & Develop.
  • Dr. Tushar Misra Ph.D. (Age 63)
    Senior VP & Chief Manufacturing Officer
    Comp: $485.89k

MRSN Stock Analysis - Frequently Asked Questions

Should I buy or sell Mersana Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MRSN shares.
View MRSN analyst ratings
or view top-rated stocks.

What is Mersana Therapeutics' stock price target for 2024?

7 Wall Street research analysts have issued 1-year price objectives for Mersana Therapeutics' shares. Their MRSN share price targets range from $5.00 to $9.00. On average, they predict the company's share price to reach $6.29 in the next year. This suggests a possible upside of 69.4% from the stock's current price.
View analysts price targets for MRSN
or view top-rated stocks among Wall Street analysts.

How have MRSN shares performed in 2024?

Mersana Therapeutics' stock was trading at $2.32 on January 1st, 2024. Since then, MRSN stock has increased by 59.9% and is now trading at $3.71.
View the best growth stocks for 2024 here
.

When is Mersana Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our MRSN earnings forecast
.

How were Mersana Therapeutics' earnings last quarter?

Mersana Therapeutics, Inc. (NASDAQ:MRSN) announced its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.16) EPS for the quarter, meeting the consensus estimate of ($0.16). The business had revenue of $10.70 million for the quarter, compared to analysts' expectations of $22.59 million. Mersana Therapeutics had a negative net margin of 465.80% and a negative trailing twelve-month return on equity of 282.36%. The company's quarterly revenue was down 27.1% on a year-over-year basis. During the same period last year, the firm earned ($0.44) EPS.

What ETF holds Mersana Therapeutics' stock?

Invesco Dorsey Wright Healthcare Momentum ETF holds 288,017 shares of MRSN stock, representing 0.81% of its portfolio.

What is Anna Protopapas' approval rating as Mersana Therapeutics' CEO?

3 employees have rated Mersana Therapeutics Chief Executive Officer Anna Protopapas on Glassdoor.com. Anna Protopapas has an approval rating of 100% among the company's employees. This puts Anna Protopapas in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Mersana Therapeutics own?
When did Mersana Therapeutics IPO?

Mersana Therapeutics (MRSN) raised $75 million in an initial public offering (IPO) on Wednesday, June 28th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

How do I buy shares of Mersana Therapeutics?

Shares of MRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MRSN) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners